Biotech Startups

Cascade Bio develops improved biocatalysts (enzymes) that are reusable, long-lasting, and offer higher output and a wider operating window compared to conventional options. Its products target industrial and commercial biocatalysis applications.

4 investors

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors. The company also targets cancer-related cachexia.

4 investors

CB Therapeutics builds a yeast platform for biosynthesis of molecules including psychedelics, cannabis, and alkaloids that are difficult to source through conventional methods. The company serves pharmaceutical and specialty chemical manufacturers.

4 investors

Cellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.

4 investors

CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.

4 investors

CellFE develops a microfluidic-based gene editing technology and a benchtop device for research and process development of cell therapies. Its products serve cell therapy researchers and developers, aiming to enable non-viral genome editing that maintains cell viability and scales from discovery to commercial manufacturing.

4 investors

Centivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.

4 investors

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.

4 investors

4 investors

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.

4 investors

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa. The company runs clinical trials for its ET-targeting therapy aimed at resolving inflammation.

4 investors

Clever Carnivore develops cultivated meat — beef, pork, and chicken grown from animal tissue samples in a food production facility — as an alternative to industrial farm-raised meat. The company targets the consumer market with cultivated meat products, including a bratwurst, focused on low-cost, scalable production.

4 investors

Coave Therapeutics is a biotech company developing gene therapies based on AAV vector engineering and genetic construct design, targeting neurodegenerative and ocular diseases. It is developing OneAAV, a universal capsid intended for next-generation gene therapy vectors.

4 investors

Coding Bio develops modular immunotherapies for cancer patients, using a high-throughput lab to screen millions of protein candidates in living cells and a machine learning platform to design and optimize therapies for immune activation. The company operates in the immuno-oncology and cell therapy space, aiming to accelerate development of CAR and related therapies.

4 investors

Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.

4 investors

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.

4 investors

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.

4 investors

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.

4 investors

Concert Bio uses DNA sequencing and a microbiome database to identify pathogens and beneficial microbes, then supplies beneficial microbes to hydroponic greenhouse growers to improve crop growth, quality, and yield. It serves hydroponic growers as an agtech platform for optimizing the plant microbiome.

4 investors

Cortical Labs develops biological computing systems by growing human neurons on chips to create a programmable computing platform. The company serves researchers and innovators seeking to accelerate medical research, reduce energy consumption in computing, and enable alternatives to animal testing.

4 investors

Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease. It pairs this delivery technology with an AI/ML nucleic acid engineering platform (NucleIQ) to design nucleic acid therapies.

4 investors

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.

4 investors

CubaseBio develops spatial biology tools that enable three-dimensional analysis of biological samples at scale, for drug discovery and biological research.

4 investors

Cumulus Oncology builds a risk-adjusted portfolio of preclinical-stage oncology drug assets, using a platform-agnostic, data- and milestone-driven curation process to advance cancer therapeutics for defined patient populations with high unmet medical need. The company aims to improve drug development success rates and create value through partnering, licensing, and exit opportunities for investors.

4 investors